Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776010 | 1.00 | LMNA (0.38) | LMNAMAPTSMN1; SMN2HPGDHCAR2 | |
| SCHEMBL4776457 | 0.80 | CYP1A2 (0.45) | MAPTSMN1; SMN2HPGD | |
| SCHEMBL4776452 | 0.80 | CYP1A2 (0.45) | MAPTSMN1; SMN2HPGD | |
| SCHEMBL4777892 | 0.78 | MAPT (0.37) | LMNAMAPTSMN1; SMN2HPGDHCAR2 | |
| SCHEMBL4777886 | 0.78 | MAPT (0.37) | LMNAMAPTSMN1; SMN2HPGDHCAR2 | |
| SCHEMBL4777885 | 0.73 | MEN1 (0.49) | LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4777889 | 0.73 | MEN1 (0.49) | LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6198084 | 0.73 | MAPT (0.44) | LMNAMAPTSMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL6198079 | 0.73 | MAPT (0.44) | LMNAMAPTSMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL6196704 | 0.73 | MAPT (0.39) | LMNAMAPTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459451-B2 | e.g. 1-Ethyl-4-(5-methyl-3-pyridyl)-6-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid; phosphodiesterase (PDE)-IV inhibitor or tumor necrosis factor (TNF)- alpha antagonist; autoimmune diseases, antidepressant, anxiolytic agent; polychondritis, scleroderma, fibrosis, arthritis, Alzheimer's disease | ASTELLAS PHARMA INC. (JP) | 2008-12-02 | — | — | US | disclosed |
| EP-1763528-B1 | PYRAZOLOPYRIDINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1763528-A1 | PYRAZOLOPYRIDINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006004188-A1 | PYRAZOLOPYRIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004003-A1 | Pyrazolopyridine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004003-A1 | Pyrazolopyridine derivatives | PDE4A, PDE3B, PDE5A | LMNA 3462/4885MAPT 2816/4885SMN1; SMN2 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.